Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 for relapsed or refractory mantle cell lymphoma
CTR20180196Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in mantle cell lymphoma (MCL), sponsored by Innovent Biologics. Started Apr 2018; status: active.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20180196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180196.